Clin2
NCT06926192Possibly a fitRecruiting

Secukinumab plus surgery for moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa (Acne Inversa)Secukinumab

Part of Infections, Skin clinical trials.

This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
Up to 80 years
Study type
Observational

Who can take part

  • You are between 18 and 80 years old.
  • You have moderate to severe hidradenitis suppurativa (Hurley stage II or III).
  • Your HS diagnosis was confirmed by a biopsy (tissue sample) at our hospital.
  • You will receive secukinumab injections along with surgery.
  • You have complete medical records and can be followed up for at least one year.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07261072Not yet recruiting· Phase 4
Comparing a shot and a cream for hidradenitis suppurativa

This study tests two ways of giving the drug secukinumab for hidradenitis suppurativa (a skin condition that causes painful boils): as a cream applied to the skin or as a shot under the skin. It looks at which works better and whether they are safe.

Nanjing, Jiangsu
NCT07109765Recruiting
Secukinumab for moderate to severe hidradenitis suppurativa

This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.

Beijing, Beijing Municipality
NCT07489573Recruiting· Phase 4
Study of secukinumab for Chinese adults with moderate-to-severe HS

This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.

Guangzhou, Guangdong
NCT07244510Recruiting· Phase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa

This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.

Samsun, Turkey
NCT07766005Not yet recruiting· Phase 2
Study of a new medicine for hidradenitis suppurativa

This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.

Irvine, California
NCT07388446Not yet recruiting
MAIT cells in hidradenitis suppurativa study

This trial looks at a type of immune cell (MAIT cells) in people with hidradenitis suppurativa (a skin condition causing painful bumps). It aims to understand how these cells work and how they relate to treatments like adalimumab, secukinumab, or bimekizumab. You may be able to join if you have moderate-to-severe HS and are about to start one of these treatments.

Lyon

Hear when a new Hidradenitis Suppurativa (Acne Inversa) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.